alexa Developing A Drug For A Disease That Doesn?t Exist: Arestvyr TM, A Smallpox Antiviral
ISSN: 1948-5964

Journal of Antivirals & Antiretrovirals
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

4th World Congress on Virology
October 06-08, 2014 Hilton San Antonio Airport, TX, USA

Dennis E Hruby
Accepted Abstracts: J Antivir Antiretrovir
DOI: 10.4172/1948-5964.S1.022
Abstract
ArestvyrTM is a smallpox antiviral drug that is in late-stage development for use as a therapeutic for symptomatic patients, prophylactic in infected but non-symptomatic patients, and for concomitant administration with smallpox vaccines to improve their safety profiles. Arestvyr is an egress inhibitor which prevents the formation of the EEV forms of orthopoxviruses. It has demonstrated excellent post-exposure efficacy in a large number of animal species that included mouse, ground squirrel, prairie dog, rabbit, and NHP challenged with a variety of different pathogenic orthopoxviruses including vaccinia, cowpox, rabbitpox, ectromelia, monkeypox and variola. In clinical studies, the drug appears to be safe and well-tolerated. Once a day oral dosing provides blood exposure at or above that which has been shown to be protective in animal studies. Following robust and iterative discussions with the regulatory authorities, a clear and achievable pathway has been mapped out for the approval of the drug for use as a therapeutic for symptomatic patients, and SIGA and its federal partners are in the process of executing this plan. Based on the data obtained to date, the U.S. government has awarded a contract to SIGA for the acquisition of two million courses of Arestvyr to be added to the Strategic National Stockpile. Work continues on the development of additional Arestvyr formulations and towards approval of the drug for additional indications.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords